Loading
A phase 1/2 trial of Perillyl alcohol in glioma & glioblastoma, run by Neonc Technologies, Inc., active and no longer recruiting.
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma is a phase 1/2 interventional study registered as NCT02704858 by Neonc Technologies, Inc., with 49 participants enrolled, started 2017-08-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Perillyl alcohol.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/